Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B

López Centeno, Beatriz; Collado Borrell, Roberto; Pérez Encinas, Montserrat; Gutiérrez García, María Luisa; Sanmartin Fenollera, Patricia.
Farm. hosp ; 40(4): 279-286, jul.-ago. 2016. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-154984

Documentos relacionados

  1. Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis.
  2. Evaluation of Pharmacokinetics of a BCS Class III Drug with Two Different Study Designs: Tenofovir Alafenamide Monofumarate Film-coated Tablet.
  3. Preparation and Characterization of 3D-Printed Dose-Flexible Printlets of Tenofovir Disoproxil Fumarate.
  4. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.
  5. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
  6. Pharmacokinetic and bioequivalence study of emtricitabine/tenofovir disoproxil fumarate tablets in healthy Chinese subjects
.
  7. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
  8. Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
  9. Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide.
  10. [LC-MS/MS Determination of Tenofovir in Human Plasma and Its Bioequivalence].